Swiss pharma giant Novartis (NOVN: VX) yesterday announced that the US District Court for the District of Delaware issued a negative decision regarding the validity of a patent covering its heart failure treatment Entresto and combinations of sacubitril and valsartan, which expires in 2025 with its pediatric exclusivity.
Novartis strongly believes the combination patent is valid and will appeal to the US Court of Appeals for the Federal Circuit (CAFC) to reverse the District Court’s decision. The company says it will continue to defend vigorously its intellectual property rights relating to Entresto, including the combination patent as well as multiple patents covering additional innovations.
Currently no generic Entresto products have tentative or final FDA approval, and the drug generated sales of $4.6 billion in 2022, a year-on-year rise of 37%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze